GLPwatch
Papers (10386)
Page 129 of 174, ranked by citation count.
- New-Onset Atrial Fibrillation Potentially Associated With Tirzepatide: A Case Report.
- Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare.
- The Effectiveness of Semaglutide on a Composite Endpoint of Glycemic Control and Weight Reduction and Its Effect on Lipid Profile Among Obese Type 2 Diabetes Patients.
- Liraglutide, a GLP-1 receptor agonist, prevents cardiovascular outcomes in patients with type 2 diabetes.
- A case of euglycaemic diabetic ketoacidosis in a T2DM patient using Tirzepatide.
- Evaluation of the hypoglycemic effect of exendin-4's new oral self-nanoemulsifying system in rats.
- Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial.
- Computational modelling the impact of GLP-1 receptor agonists on botulinum toxin A: Evidence for reduced treatment durability across neurologic and aesthetic indications.
- Tirzepatide-induced weight loss and obstructive sleep apnea improvement in an adult with type 2 diabetes: A case report.
- Semaglutide and risk of suicidal ideations.
- Glucagon-like peptide-1 receptor agonists and hair loss: An emerging clinical concern.
- Adipocytic sclerostin loop3-LRP4 interaction required by sclerostin to impair whole-body lipid and glucose metabolism.
- Use of glucagon-like peptide-1 receptor agonists among individuals on basal insulin requiring treatment intensification.
- Semaglutide augments vascular proliferation and cardiac performance in a large animal model of ischemic cardiomyopathy.
- Effectiveness and adherence in a tirzepatide-supported digital weight-loss programme in Australia: A real-world observational study.
- Medicare Should Cover Weight Loss Drugs as Long as the Prices are Affordable.
- Can small molecule GLP-1 agonists be the next first-line drugs in type-2 diabetes mellitus?
- Unveiling Tirzepatide's Therapeutic Spectrum: A Dual GIP/GLP-1 Agonist Targeting Metabolic, Neurological, and Cardiovascular Health.
- Patient experiences with liraglutide for obesity and binge eating disorder-A qualitative study.
- Redistribution of Proximal and Distal Reabsorption of Water and Ions in Rat Kidney After Treatment with Glucagon-Like Peptide-1 Mimetic.
- Evaluating Suicidal Risk in GLP-1RA Therapy: An Umbrella Review of Meta-Analytic Evidence.
- One-year Efficacy and Safety of Dulaglutide in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Retrospective Study of Asian Patients.
- Data-driven prioritization of high-risk individuals for weight loss interventions.
- Utilization patterns of glucagon like Peptide-1 receptor agonists prior to bariatric and metabolic surgery: a multicenter study.
- Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial.
- Liraglutide mitigates dexamethasone-induced fatty acid synthase (FASN) and the cluster of differentiation36 (CD36) expression: a potential treatment for glucocorticoid-induced non-alcoholic fatty liver disease (NAFLD).
- Impact of Semaglutide 2.4 mg on Healthcare Resource Utilization and Medical Costs in Patients With Heart Failure in the United States (SHINE-HF).
- Quantitative analysis of the efficacy characteristics and influencing factors of weight loss drugs in children and adolescents.
- Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial.
- Exendin-4 induced retching-like behavior mediated by postsynaptic effect via AMPA receptors in the area postrema of mice.
- Intragastric injection botulinum toxin A for obesity management with or without liraglutide.
- In type 2 diabetes with increased CV risk, tirzepatide reduced HbA<sub>1c</sub> vs. glargine at 52 wk.
- Effect of bariatric surgery and pharmacological treatments on cardiovascular risk factors for adults with overweight and obesity: a systematic review and network meta-analysis.
- Interaction Between Glucagon-like Peptide 1 and Its Analogs with Amyloid-β Peptide Affects Its Fibrillation and Cytotoxicity.
- Impact of insulin sensitivity, beta-cell function and glycaemic control on initiation of second-line glucose-lowering treatment in newly diagnosed type 2 diabetes.
- The Use of Exenatide in Managing Markers of Cardiovascular Risk in Patients with Type 2 Diabetes: A Systematic Review.
- Safe use of a once-a-week glucagon-like peptide-1 receptor agonist in a 16-year-old girl with type 2 diabetes when approved therapy options fail.
- Exendin-4 intervention attenuates atherosclerosis severity by modulating myeloid-derived suppressor cells and inflammatory cytokines in ApoE<sup>-/-</sup> mice.
- GLP-1 agonists in neurodegeneration: a multimodal biomarker-guided approach.
- The effect of liraglutide on cardiac autonomic function in type 2 diabetes: A prespecified secondary analysis from the LIRAFLAME randomized, double-blinded, placebo-controlled trial.
- GLP-1 RA Medication Associations With Hazardous Alcohol Drinking Reductions in Patients With Overweight or Obesity: A Prospective Observational Study.
- Semaglutide and weight loss - A concern for diabetics and pharmaceuticals.
- Case Report: Rhabdomyolysis following initiation of tirzepatide.
- Once-weekly semaglutide use in glucagon-like peptide-1 receptor agonist naïve patients with type 2 diabetes in North Macedonia: Real-world data from the MIRAGE study.
- Study: Semaglutide Lowered Chronic Kidney Disease-Related Risks.
- Inference for Cumulative Incidences and Treatment Effects in Randomized Controlled Trials With Time-to-Event Outcomes Under ICH E9 (R1).
- Exenatide implant therapy in diabetes.
- Bone morphogenetic protein-9 maybe an important factor which improves insulin resistance in PCOS.
- [GLP-1-based medications: Mechanisms involved in obesity treatment].
- [Contribution of metabolic sensors on feeding behaviour and the control of body weight].
- Semaglutide reduces the absolute risk of major cardiovascular events by 1.5.
- Improved Clinical Outcomes with the Combination Therapy of a Glucagon-like Peptide-1 Receptor Agonists and a Sodium-glucose Cotransporter-2 Inhibitor in Overweight/Obese People with Type 2 Diabetes: Real-world Evidence from the Indian Subcontinent.
- Effects of glucagon-like peptide 1 receptor signaling in the dorsolateral septum on ethanol operant self-administration and relapse behaviors.
- Developing a novel algorithm to identify incident and prevalent dementia in Medicare claims-the ARIC Study.
- [Potentiation of weight reduction with GLP-1 receptor agonists].
- Lixisenatide as add-on to insulin glargine for the treatment of type 2 diabetes mellitus.
- Time-in-range derived from self-measured blood glucose in people with type 2 diabetes advancing to iGlarLixi: A participant-level pooled analysis of three phase 3 LixiLan randomized controlled trials.
- Effects of intraportal exenatide on hepatic glucose metabolism in the conscious dog.
- Usefulness of Empagliflozin Versus Oral Semaglutide for Prevention of Cardiovascular Mortality in Patients With Type 2 Diabetes Mellitus.
- Incretin based therapeutics: connections to vascular biology and implications for potential cardiovascular disease prevention: Editorial to: "Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation" by Dai et al.